ZIM
ANIP icon

Zacks Investment Management’s ANI Pharmaceuticals ANIP Stock Holding History

Zacks Investment Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,339
Closed -$369K – 630
2024
Q1 		$369K Buy
+5,339
New +$322K ﹤0.01% 514
2016
Q4 		– Sell
-10,267
Closed -$681K – 639
2016
Q3 		$681K Buy
+10,267
New +$642K 0.02% 411

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zacks Investment Management's ANIP Position: Q2 2024 in Review

Zacks Investment Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2024, closing a stake of 5,339 shares — an estimated $369K sold.

Zacks Investment Management first reported a position in ANIP in Q3 2016 and held it in 2 quarters. The position peaked at $681K in Q3 2016. 201 funds tracked by Wall St. Rank hold ANIP as of Q2 2024.

  • Zacks Investment Management reported no remaining ANI Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Zacks Investment Management sold 5,339 ANI Pharmaceuticals shares in Q2 2024, an estimated $369K.
  • Zacks Investment Management first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Zacks Investment Management's ANI Pharmaceuticals position peaked at $681K in Q3 2016.
  • 201 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2024.

Based on Zacks Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.